Bristol Myers Squibb Stock Revenue
| BMYMP Stock | USD 1,006 0.00 0.00% |
Bristol Myers Squibb fundamentals help investors to digest information that contributes to Bristol-Myers Squibb's financial success or failures. It also enables traders to predict the movement of Bristol-Myers Pink Sheet. The fundamental analysis module provides a way to measure Bristol-Myers Squibb's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol-Myers Squibb pink sheet.
Bristol-Myers |
Bristol Myers Squibb Company Revenue Analysis
Bristol-Myers Squibb's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Bristol-Myers Squibb Revenue | 46.38 B |
Most of Bristol-Myers Squibb's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Bristol Myers Squibb reported 46.38 B of revenue. This is much higher than that of the Healthcare sector and 110.99% higher than that of the Drug Manufacturers - Major industry. The revenue for all United States stocks is significantly lower than that of the firm.
Bristol-Myers Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol-Myers Squibb's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bristol-Myers Squibb could also be used in its relative valuation, which is a method of valuing Bristol-Myers Squibb by comparing valuation metrics of similar companies.Bristol Myers is currently under evaluation in revenue category among its peers.
Bristol-Myers Fundamentals
| Revenue | 46.38 B | |||
| EBITDA | 20.1 B | |||
| Net Income | 7.01 B | |||
| Cash And Equivalents | 6.07 B | |||
| Cash Per Share | 3.72 X | |||
| Total Debt | 39.6 B | |||
| Debt To Equity | 59.40 % | |||
| Current Ratio | 1.40 X | |||
| Book Value Per Share | 7.55 X | |||
| Cash Flow From Operations | 16.21 B | |||
| Number Of Employees | 23.7 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 2.11 T | |||
| Total Asset | 109.31 B | |||
| Annual Yield | 0 % | |||
| Net Asset | 109.31 B | |||
| Last Dividend Paid | 1.59 |
About Bristol-Myers Squibb Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol-Myers Squibb using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bristol-Myers Squibb
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol-Myers Pink Sheet
Moving against Bristol-Myers Pink Sheet
| 0.91 | TLK | Telkom Indonesia Tbk | PairCorr |
| 0.86 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.84 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.81 | TCHH | Trustcash Holdings | PairCorr |
| 0.81 | HYMTF | Hyundai Motor | PairCorr |
The ability to find closely correlated positions to Bristol-Myers Squibb could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol-Myers Squibb when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol-Myers Squibb - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol-Myers Squibb is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol-Myers Squibb moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol-Myers Squibb can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Bristol-Myers Pink Sheet Analysis
When running Bristol-Myers Squibb's price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.